Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959705 | 0.93 | CYP1A2 (0.41) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL5664086 | 0.83 | TSHR (0.41) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL9701509 | 0.81 | PPARD (0.47) | TSHRPPARD | |
| SCHEMBL9701504 | 0.80 | PPARD (0.46) | LMNAPPARD | |
| SCHEMBL9700806 | 0.80 | PPARD (0.46) | LMNAPPARD | |
| SCHEMBL9702638 | 0.80 | PPARD (0.46) | LMNAPPARD | |
| Water SCHEMBL9701709 | 0.79 | PPARD (0.44) | LMNAPPARD | |
| SCHEMBL9062818 | 0.79 | GABBR2 (0.55) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL9700840 | 0.77 | LPAR3 (0.42) | LMNATSHRPPARD | |
| SCHEMBL5701855 | 0.77 | S1PR2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103161-A1 | Novel heterocycles | ARIAD PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103161-A1 | Novel heterocycles | BMP2, SOST, BMP4 | LMNA 2935/4885BLM 2567/4885CYP3A4 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.